![Assoc. Dr. Furkan Sarici, [object Object]](/_next/image?url=https%3A%2F%2Fs3-ap-south-1.amazonaws.com%2Fimages.hospals.com%2Fimages%2Fdoctors%2Fdefault_doctor.png&w=3840&q=60)
Assoc. Dr. Furkan Sarici
Medical Oncologist
Consults at:
4.5
Surgeries
N/A
Experience
15+ years
FAQs
Assoc. Dr. Furkan Sarici is a Medical Oncologist.
Medical Oncologist
Consults at:
4.5
Assoc. Dr. Furkan Sarici is a Medical Oncologist.
Medical Interests
Hacettepe University Faculty of Medicine
Place and Year of Specialization Training
Hacettepe University Faculty of Medicine
Hacettepe University Faculty of Medicine Internal Medicine 2006-2011
Hacettepe University Faculty of Medicine Oncology 2011-2015
SBU Konya Education Research Hospital 2015-2016
Medicana International Ankara Hospital 2016-2018
Istinye University Medical Faculty. – Medical Park Trabzon Hospital (2018-2020)
Scientific Publications
1) Sarici F, Sunar V, Aksoy S. The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer. International Journal of Hematology and Oncology 2020; 30(1):1-10.
2) Sarici F, Babacan T, Buyukhatipoglu H et al. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. J BUON.2016;21(4):826-31.
3)Sarici F, Kertmen N, Aslan A, Tasdemir V, Babacan T, Kilickap S, Ozdemir E, Barista İ, Turker A, Kars A.
Anthracyclin – Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. International Journal of Hematology and Oncology 2016; 26(2):089-095.
4)Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K.Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375-81.
5)Ates O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, Sever AR, Altundag K.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. springerplus. 2016;19(5):486.
6) Sarici F, Babacan T, Altudag K, Balakan O, GulluI. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON.2013;18(3):799.
7)Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundag K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality . J BUON.2015;20(3):737-45.
8)Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON.2015;20(1):50-6.
9) Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori.2015;101(4):418-23.
10) Sarici F, Babacan T, Petekkaya I, Gezgen G, Roach EC, Altundag K. Colon involvement in a chronic lymphocytic leukemia patient. J BUON. 2013;18(1):291-2.
11) Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akın S, Arik Z, Aslan A, Ates O, Aksoy S, Ozisik Y, Altundag K. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON. 2015;20(1):35-9.
Memberships of Association
of Internal Medicine Specialists Association of
Medical Oncology
Ankara Medical Chamber (Turkish Medical Association)
Chat Now